

# Skin Disease-Oriented Team

---

## Clinical Research Treatment Flowchart

**Clinical Research Manager:**  
Mehir Tharani

**Clinical Research Coordinators:**  
Bao-An Huynh  
Natalie Arechiga  
Erin Palmer-Torrison  
Anastasiia Reipolska

## First Line, Resectable

### SWOG 2015

1cm v 2cm margin  
PI: Yamamoto  
CRC: N. Arechiga  
Accrual: 18/30

## Adjuvant, Stage 2

### UCI 23-220

Pembro vs Biosimilar  
PI: Chow  
CRC: E. Palmer-Torrison  
Accrual: 0/10

## First Line, Stage 3 Neoadjuvant + Adjuvant

### UCI 23-220

Adjuvant Pembro vs  
Biosimilar  
PI: Chow  
CRC: E. Palmer-Torrison  
Accrual: 0/10

### UCI 24-123

Fianlimab + Cemiplimab +  
Sx  
PI: Chow  
CRC: TBD  
Accrual: 0/29

## First Line, Metastatic or unresectable without previous CPI

### EA6141

(III or IV)  
Ipi + Nivo + sargramostin **vs.**  
Ipi + Nivo  
PI: Chow  
CRC: A. Reipolska  
Accrual: 4/7

## 2<sup>nd</sup> Line + Metastatic or unresectable

### UCI 22-49

Pembro + Cyclophosphamide  
PI: Chow  
CRC: B. Huynh  
Accrual: 1/14

### UCI 24-112

Vusolimogene Oderparepvec  
(HSV-1) + Nivo **vs.**  
Physician's Choice  
PI: Tran  
CRC: A. Reipolska  
Accrual: 0/5

### UCI 23-218

[212 Pb] VMT01 ± Nivo  
PI: Srinivas  
CRC: TBD  
Accrual: 0/5

Open

Low Accrual

Pending  
Activation  
or  
Suspended

Consider Broad Phase 1 Studies

UCI 21-40

DF6002 (IL-12) monotherapy  
and combo (Nivolumab)  
PI: Valerin  
CRC: B. Huynh  
Accrual: 5/10  
Waitlist

UCI 23-197

DF6215 (IL-2)  
PI: Valerin  
CRC: N. Arechiga  
Accrual: 4/5  
Waitlist

UCI 24-82

MEK/RAF Inhibitors  
(RAS/RAF mutation  
NRAS or BRAF class II or III)  
PI: Valerin  
CRC: C. Kang  
Accrual: 8/10

UCI 23-148

CJRB-101 (*L. mesenteroides*) + Pembro  
PI: Nagasaka  
CRC: J. Choe  
Accrual: 3/6  
Accrual pause until ~July 2025

Open

Low Accrual

Pending  
Activation  
or  
Suspended

Non-interventional Trials

UCI 19-135  
DecisionDx-Melanoma Impact on  
Sentinel Lymph Node Biopsy Decisions  
and Clinical Outcomes (DECIDE)  
PI: Yamamoto  
CRC: Anastasiia R.  
Accrual: 86/90

UCI 23-149  
Multiphoton Microscopy Imaging as a  
Tool to Monitor Immune Activation  
Induced by Checkpoint Inhibitors  
PI: Ganesan  
Contact: Hira Rizwi  
Accrual: 4/15

UCI 23-93  
Assessment of ICOS as a Novel Biomarker  
to Determine Response and Resistance of  
Checkpoint Immunotherapy for Cutaneous  
Malignancies  
PI: Tran  
Target Accrual: 0/15

Recurrent

**ETCTN 10592**  
M1774 +/- avelumab  
PI: Gao  
CRC: N. Arechiga  
Accrual: 3/5

Open

Low Accrual

Pending  
Activation  
or  
Suspended

Broad Phase 1 trials

UCI 21-40

DF6002 (IL-12) monotherapy and combo (Nivolumab)

PI: Valerin

CRC: B. Huynh

Accrual: 5/10

Waitlist

Non-interventional Trials

UCI 11-30

(IRB 2008-6307)

Skin Imaging with Technologies in Development

PI: Kelly

Accrual: 638/750

UCI 13-13

(IRB 2011-8494)

In-Vivo Non-Invasive Skin Imaging Using  
Multiphoton Microscopy and Multispectral Imaging

PI: Kelly

Accrual: 206/250

UCI 25-68

Understanding Barriers to Skin Cancer in AAPI

PI: Tran

CRC: TBD

Accrual: 0/10

Interventional Trials

UCI 23-153

Topical HT-001 for Skin Toxicities w/EGFR Inhib.

PI: Smith

CRC: B. Huynh

Accrual: 2/16

UCI 25-57

Neoadjuvant Opdualag vs. Nivolumab for  
Resectable High-Risk BCC

PI: Vaidya

CRC: TBD

Accrual: 0/5

UCI 25-08

Laser treatment for Stage 1 BCC

PI: Zachary

CRC: TBD

Accrual: 0/20

Open

Low Accrual

Pending  
Activation  
or  
Suspended